Equillium, Inc. (EQ): Nasdaq/NYSE listing notice — Equillium receives Nasdaq extension to Dec 8, 2025 for bid price compliance

Equillium, Inc.

Nasdaq granted Equillium (EQ) until Dec 8, 2025 to regain minimum $1.00 bid price compliance.
Original 180-day compliance period ended June 11, 2025; extension provides additional 180 calendar days.
If not compliant by Dec 8, 2025, staff will issue delisting notice; company may appeal to hearings panel.
Company will monitor bid price and consider reverse stock split or other options to regain compliance.
Stock continues trading on Nasdaq Capital Market under symbol EQ; no immediate delisting effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 13, 2024, Equillium, Inc. (the “ Company ” ) received a notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). The Company was given 180 days, or until June 11, 2025, to regain compliance with the Minimum Bid Price Requirement. On June 12, 2025, the Company received a notice from Nasdaq that the Company was granted an additional 180 calen

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-086155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.